AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Rhea-AI Summary

AC Immune announced ten presentations at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. The company is focused on precision medicine for neurodegenerative diseases, highlighting progress in Alzheimer's and Parkinson's treatments. Chief Medical Officer Johannes Streffer will discuss immunotherapies at the event. The CEO emphasized the advancements in their vaccine pipeline and the potential for significant market impact. AC Immune's pipeline includes first- and best-in-class assets, with several candidates in Phase 2 and 3 clinical trials, underscoring their commitment to innovative treatments.

Positive

• Ten presentations scheduled at the AD/PD 2023 conference showcase AC Immune's advancements.
• Participation in expert forums enhances visibility and credibility in immunotherapy research.
• Strong pipeline including ten therapeutic and three diagnostic candidates, five in Phase 2 trials and one in Phase 3.

Negative

• None.

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

• Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD^TM)
• AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s disease

Lausanne, Switzerland, March 20, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD^TM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC Immune, will join an expert panel to discuss the latest developments in immunotherapies in Alzheimer’s disease.

Andrea Pfeifer, Ph.D., CEO of AC Immune SA, commented: “The ten presentations during this AD/PD^TM conference demonstrate AC Immune’s progress towards our over-arching goal, which is to shift the treatment paradigm towards Precision Medicine and disease prevention. As our clinical programs in Alzheimer’s and Parkinson’s diseases are advancing, we are solidifying our position as a leading developer of vaccines for neurodegenerative diseases. AC Immune’s cutting-edge therapeutic and diagnostic research programs pursuing multiple validated molecular targets, highlight the breadth of our pipeline. These will drive our differentiated Precision Medicine approach in neurodegeneration and become substantial value creating catalysts.”

AC Immune presentations at AD/PD^TM2023 (all times are CEST)

Roundtable discussion
Forum 02: Immunotherapies in AD: from basics to approval
Date: Wed, 29.03.2023 | 03:55 PM - 04:55 PM | Hall C
Panelist: Forum discussion with Johannes Streffer, M.D., (AC Immune)

Active immunotherapy
ABATE study – Utilizing biomarker-based development for optimized ACI-24, a novel candidate vaccine for the treatment and prevention of Alzheimer’s disease
Date: Sat, 01.04.2023 | 05:55 PM - 06:10 PM | Hall G3
Presenter: Oral presentation by Johannes Streffer, M.D., (AC Immune)

Beneficial effect of ACI-24 vaccination on Abeta plaque pathology and microglial phenotypes in an amyloidosis mouse model
Date: Sat, 01.04.2023 | 09:25 AM - 09:40 AM | Hall G4
Presenter: Oral presentation by Sabina Tahirovic, Ph.D., (German Center for Neurodegenerative Diseases)

A novel anti-amyloid beta (Abeta) vaccine, a potent immunotherapy for the prevention and treatment of Alzheimer’s disease in Down syndrome
Date: Sat., 01.04.2023 | 07:00 AM – 08:30 AM | OD349 / #1688
Presenter: On-demand symposium by Emma Fiorini, Ph.D. (AC Immune)

VacSYn study design – biomarker-based development for ACI-7104, a novel candidate vaccine for the treatment and prevention of Parkinson’s disease
Date: Available online from Tue, 28.03.2023 | Poster P0313 / #1791
Presenter: On demand presentation by Dymitr Kostrica, Ph.D. (AC Immune)

Passive immunotherapy
Antibody-mediated inhibition of ASC attenuates inflammasome activation in vitro and in a mouse model of demyelination
Date: Wed, 29.03.2023 | 04:15 PM - 04:30 PM | Hall G4
Presenter: Oral presentation by Davide Basco, Ph.D. (AC Immune)

Development of TDP-43 immunotherapy blocking transmission of seeding-competent species from ALS/FTD
Date: Thu, 30.03.2023 | 06:05 PM - 06:20 PM | Hall G3
Presenter: Oral presentation by Tariq Afroz, Ph.D. (AC Immune)

Small molecules
Discovery of therapeutic small molecules targeting alpha-synuclein aggregation
Date: Fri, 31.03.2023 | 07:00 AM – 08:30 AM | OD209 / #1442
Presenter: On demand presentation by Elpida Tsika, Ph.D. (AC Immune)

Diagnostics & biomarkers
Discovery and initial clinical evaluation [18F]ACI-12589, a novel and promising PET-tracer for a-synuclein
Date: Thu, 30.03.2023 | 09:40 AM - 09:55 AM | Hall F4+F5
Presenter: Oral presentation by Francesca Capotosti, Ph.D. (AC Immune)

Compartmentalization of plasma TDP-43 in platelets: implications for TDP-43-related biomarker development
Date: Thu, 30.03.2023 | 02:05 PM - 02:20 PM | Hall G3
Presenter: Oral presentation by Ruth Luthi-Carter, Ph.D. (AC Immune)

Optimization of affinity, selectivity and pharmacokinetic profile of TDP-43 PET ligands
Date: Available online from Tue, 28.03.2023 | Poster P0994 / #979
Presenter: On demand presentation by Tamara Seredenina, Ph.D. (AC Immune)

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen^® and Morphomer^®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.

SupraAntigen^® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer^® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

Head of Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com	U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com
International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com

Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

• 20230320-ADPD2023_curtain-raiser-FINAL

FAQ

What will AC Immune present at AD/PD 2023?

AC Immune will deliver ten presentations related to their precision medicine pipeline targeting Alzheimer's and Parkinson's diseases.

Who is representing AC Immune at the AD/PD 2023 conference?

AC Immune's Chief Medical Officer, Johannes Streffer, will participate in an expert panel discussion.

What is the focus of AC Immune's research presented at the conference?

The research focuses on immunotherapies and novel vaccine candidates for the treatment and prevention of Alzheimer's and Parkinson's diseases.

How many candidates are currently in clinical trials for AC Immune?

AC Immune has five candidates in Phase 2 clinical trials and one in Phase 3.

What is AC Immune's goal related to neurodegenerative diseases?

AC Immune aims to shift toward precision medicine and disease prevention in neurodegenerative diseases.